L. Österberg

External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas

K. Partheen, G. Horvath, K. Sundfeldt, 2009, BMC Cancer.

Chromosomal alterations in 98 endometrioid adenocarcinomas analyzed with comparative genomic hybridization

K. Helou, K. Partheen, G. Horvath, 2006, Cytogenetic and Genome Research.

Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas

Björn Olsson, György Horvath, B. Olsson, 2009, BMC Cancer.

High-Resolution Genomic Profiling of Carboplatin Resistance in Early-Stage Epithelial Ovarian Carcinoma

J. Staaf, K. Partheen, G. Horvath, 2009, Cytogenetic and Genome Research.

Characterization of genetic alterations in ovarian cancer associated with chemotherapy response

L. Österberg, 2009 .

Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage

K. Helou, K. Partheen, G. Horvath, 2004, Genes, chromosomes & cancer.

Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas

K. Partheen, G. Horvath, K. Sundfeldt, 2008, International journal of cancer.